Publicaciones científicas

58 Publicaciones científicas disponibles

  • Performance Comparison of Two Next-Generation Sequencing Panels to Detect Actionable Mutations in Cell-Free DNA in Cancer Patients

    28 de julio de 2020 | Revista: Clinical Chemistry and Laboratory Medicine

    Mónica Macías  (1) , Eva Cañada-Higueras  (2) , Estibaliz Alegre  (1, 3) , Arancha Bielsa  (2) , Javier Gracia  (2) , Ana Patiño-García  (2, 3, 4) , Roser Ferrer-Costa  (5) , Teresa Sendino  (1) , María P Andueza  (6) , Beatriz Mateos (1) , Javier Rodríguez  (3, 6) , Jesús Corral  (2) , Alfonso Gúrpide  (3, 6) , José M Lopez-Picazo  (3, 6) , Jose L Perez-Gracia  (3, 6) , Ignacio Gil-Bazo  (3, 6, 7, 8) , Gorka Alkorta-Aranburu (2) , Álvaro González  (1, 3)

    (1) Service of Biochemistry, Clínica Universidad de Navarra, Pamplona, Spain.
    (2) CIMA LAB Diagnostics Universidad de Navarra, Pamplona, Spain.
    (3) IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.
    (4) Department of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain.
    (5) Department of Biochemistry, Hospital Universitari Vall D'Hebron, Universitat Autònoma De Barcelona, Barcelona, Spain.
    (6) Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
    (7) Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
    (8) Program of Solid Tumors, Center for Applied Medical Research, University of Navarra, Pamplona, Spain.


  • Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors

    11 de mayo de 2020 | Revista: Nature Medicine

    Schalper KA (1), Carleton M (2), Zhou M (3), Chen T (3), Feng Y (3), Huang SP (3), Walsh AM (4), Baxi V (4), Pandya D (5), Baradet T (2), Locke D (2), Wu Q (5), Reilly TP (5), Phillips P (2), Nagineni V (6), Gianino N (6), Gu J (7), Zhao H (7), Perez-Gracia JL (8,9), Sanmamed MF (8,9,10,11), Melero I (12,13,14).

    (1) Department of Pathology, Yale University School of Medicine, New Haven, CT, USA. kurt.schalper@yale.edu.
    (2) Department of Translational Medicine, Bristol-Myers Squibb, Princeton, NJ, USA.
    (3) Department of Global Biometric Sciences, Bristol-Myers Squibb, Princeton, NJ, USA.
    (4) Department of Translational Bioinformatics, Bristol-Myers Squibb, Princeton, NJ, USA.
    (5) Department of Research and Early Development, Bristol-Myers Squibb, Princeton, NJ, USA.
    (6) Department of Pathology, Yale University School of Medicine, New Haven, CT, USA.
    (7) Department of Biostatistics, School of Public Health, Yale University, New Haven, CT, USA.
    (8) Oncology Department, Clinica Universidad de Navarra, Pamplona, Spain.
    (9) Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
    (10) Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.
    (11) Department of Immunology and Immunotherapy, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.
    (12) Oncology Department, Clinica Universidad de Navarra, Pamplona, Spain.
    (13) Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
    (14) Department of Immunology and Immunotherapy, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, Pamplona, Spain.


  • CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity

    6 de abril de 2020 | Revista: Immunity

    Teijeira Á (1), Garasa S (2), Gato M (3), Alfaro C (4), Migueliz I (2), Cirella A (2), de Andrea C (5), Ochoa MC (6), Otano I (3), Etxeberria I (3), Andueza MP (7), Nieto CP (2), Resano L (7), Azpilikueta A (4), Allegretti M (8), de Pizzol M (8), Ponz-Sarvisé M (9), Rouzaut A 6, Sanmamed MF 6, Schalper K 10, Carleton M (11), Mellado M (12), Rodriguez-Ruiz ME ()6, Berraondo  P (6), Perez-Gracia JL (7), Melero I (13).

    (1) Program for Immunology and Immunotherapy Department, CIMA, Universidad de Navarra, 31008 Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Navarra Institute for Health Research (IDISNA), 31008 Pamplona, Spain.
    (2) Program for Immunology and Immunotherapy Department, CIMA, Universidad de Navarra, 31008 Pamplona, Spain.
    (3) Program for Immunology and Immunotherapy Department, CIMA, Universidad de Navarra, 31008 Pamplona, Spain; Navarra Institute for Health Research (IDISNA), 31008 Pamplona, Spain.
    (4 Program for Immunology and Immunotherapy Department, CIMA, Universidad de Navarra, 31008 Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
    (5) Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Navarra Institute for Health Research (IDISNA), 31008 Pamplona, Spain; Department of Oncology, Clinica Universidad de Navarra, 31008 Pamplona, Spain.
    (6) Program for Immunology and Immunotherapy Department, CIMA, Universidad de Navarra, 31008 Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Navarra Institute for Health Research (IDISNA), 31008 Pamplona, Spain.
    (7) Department of Oncology, Clinica Universidad de Navarra, 31008 Pamplona, Spain.
    (8) Dompé Farmaceutici S.p.A., 20122 Milano, Italy.
    (9) Navarra Institute for Health Research (IDISNA), 31008 Pamplona, Spain; Department of Oncology, Clinica Universidad de Navarra, 31008 Pamplona, Spain.
    (10) Department of Pathology, Yale University School of Medicine, New Haven, CT 06520, USA.
    (11) Bristol Myers Squibb, Lawrence Township, NJ 08648, USA.
    (12) Chemokine Signaling Group, Department of Immunology and Oncology, Centro Nacional de Biotecnología (CNB-CSIC), 28049 Madrid, Spain.
    (13) Program for Immunology and Immunotherapy Department, CIMA, Universidad de Navarra, 31008 Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Navarra Institute for Health Research (IDISNA), 31008 Pamplona, Spain.


  • Cellular cytotoxicity is a form of immunogenic cell death

    8 de marzo de 2020 | Revista: Journal Immunotherapy Cancer

    Minute L (1,2), Teijeira A (1,2,3), Sanchez-Paulete AR (1,2), Ochoa MC (1,2,3), Alvarez M (1,2), Otano I (1,2), Etxeberrria I (1,2), Bolaños E (1,2), Azpilikueta A (1,2), Garasa S (1,2), Casares N (1,2), Luis Perez Gracia J (2,4), Rodriguez-Ruiz ME (1,2,4), Berraondo P (5,2,3), Melero I (5,2,3,4).

    (1) Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.
    (2) Navarra Institute for Health Research (IDISNA), Pamplona, Spain.
    (3) Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
    (4) Departments of Oncology and Immunology, Clínica Universidad de Navarra, Pamplona, Spain.
    (5) Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.